Table 1 Patient demographics and clinical characteristics at time of enrolment
Demographic variable | Cohort 1 (n = 21) | Cohort 2 (n = 34) |
|---|---|---|
Female | 19 (90 %) | 31 (91 %) |
Age, median (interquartile range) | 41.0 (34.3–51.3) | 44.5 (36.0–52.0) |
Samples per patient, median (range) | 4 (2–7) | 1 (1–1) |
Follow-up duration (months), median (interquartile range) | 16.5 (12.0–21.3) | − |
Active SLE disease features | ||
Cutaneous | 10 (48 %) | 19 (56 %) |
Arthritis | 4 (19 %) | 13 (38 %) |
Serositis | 5 (24 %) | 2 (6 %) |
Renal | 12 (57 %) | 11 (32 %) |
Neurologic | 5 (24 %) | 3 (9 %) |
Haematologic | 16 (76 %) | 17 (50 %) |
dsDNA-positive | 15 (71 %) | 19 (56 %) |
Low C3/C4 | 13 (62 %) | 15 (44 %) |
Other SLE serology | ||
ANA-positive | 17 (81 %) | 33 (97 %) |
Ro/La-positive | 4 (19 %) | 18 (53 %) |
Sm/RNP-positive | 3 (14 %) | 22 (65 %) |
Active treatment | ||
Initial prednisolone dose (mg/day), median (range) | 15 (0-35) | 5 (0-25) |
Maintenance prednisolone dose (mg/day), median (range) | 7.5 (0-30) | − |
Mycophenolate mofetil | 11 (52 %) | 9 (26 %) |
Azathioprine | 10 (48 %) | 6 (18 %) |
Hydroxychloroquine | 10 (48 %) | 19 (56 %) |
Methotrexate | 0 (0 %) | 6 (18 %) |
Tacrolimus/everolimus | 0 (0 %) | 2 (6 %) |
Previous treatment | ||
Intravenous cyclophosphamide | 11 (52 %) | 3 (9 %) |
Intravenous immunoglobulin | 2 (10 %) | 0 (0 %) |